Bone marrow changes in patients with refractory aplastic anemia treated by recombinant GM-CSF

F. Naeim, R. Champlin, Stephen D Nimer

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The morphologic changes in the bone marrow of eight patients with refractory aplastic anemia who received 4 or more weeks of granulocyte macrophage-colony-stimulating factor (GM-CSF) are described. All eight patients demonstrated a continuous rise in the absolute number of neutrophils, eosinophils, and monocytes over the first four weeks of therapy. Bone marrow examination revealed a progressive increase in bone marrow cellularity in all patients except one. An increase in myeloid: erythroid ratio was seen with progressive maturation of granulocytic cells. Neutrophilic and eosinophilic myelocytes were the most prominent cells. The percentage of myeloblasts and promyelocytes did not increase significantly, and the proportions of postmitotic granulocytic cells did not change either. No significant morphologic changes were noted in the basophilic, erythroid, and megakaryocytic series. The most prominent topographic observation in the bone marrow during GM-CSF therapy was the frequent clustering of myeloid cells close to the bone trabeculae. The periosteal localization of myeloid precursors may reflect a higher concentration of stem cells and/or stromal cells in the bone marrow adjacent to the bone trabeculae or a higher concentration of growth factors. Careful morphologic examination of bone marrow in CSF clinical trials will provide useful information regarding the in vivo effects of these growth factors, and will aid in the development of a rational approach to combining them for therapy.

Original languageEnglish
Pages (from-to)79-85
Number of pages7
JournalHematologic Pathology
Volume4
Issue number2
StatePublished - Jan 1 1990
Externally publishedYes

Fingerprint

Refractory Anemia
Granulocyte Precursor Cells
Aplastic Anemia
Granulocyte-Macrophage Colony-Stimulating Factor
Bone Marrow Examination
Bone Marrow
Intercellular Signaling Peptides and Proteins
Bone and Bones
Myeloid Cells
Mesenchymal Stromal Cells
Eosinophils
Cluster Analysis
Monocytes
Neutrophils
Stem Cells
Therapeutics
Observation
Clinical Trials

Keywords

  • Aplastic anemia
  • Bone marrow topography
  • GM-CSF
  • Hematopoiesis

ASJC Scopus subject areas

  • Hematology
  • Pathology and Forensic Medicine

Cite this

Bone marrow changes in patients with refractory aplastic anemia treated by recombinant GM-CSF. / Naeim, F.; Champlin, R.; Nimer, Stephen D.

In: Hematologic Pathology, Vol. 4, No. 2, 01.01.1990, p. 79-85.

Research output: Contribution to journalArticle

@article{e6cb9ccd5d1b4394acca3bee99bd500b,
title = "Bone marrow changes in patients with refractory aplastic anemia treated by recombinant GM-CSF",
abstract = "The morphologic changes in the bone marrow of eight patients with refractory aplastic anemia who received 4 or more weeks of granulocyte macrophage-colony-stimulating factor (GM-CSF) are described. All eight patients demonstrated a continuous rise in the absolute number of neutrophils, eosinophils, and monocytes over the first four weeks of therapy. Bone marrow examination revealed a progressive increase in bone marrow cellularity in all patients except one. An increase in myeloid: erythroid ratio was seen with progressive maturation of granulocytic cells. Neutrophilic and eosinophilic myelocytes were the most prominent cells. The percentage of myeloblasts and promyelocytes did not increase significantly, and the proportions of postmitotic granulocytic cells did not change either. No significant morphologic changes were noted in the basophilic, erythroid, and megakaryocytic series. The most prominent topographic observation in the bone marrow during GM-CSF therapy was the frequent clustering of myeloid cells close to the bone trabeculae. The periosteal localization of myeloid precursors may reflect a higher concentration of stem cells and/or stromal cells in the bone marrow adjacent to the bone trabeculae or a higher concentration of growth factors. Careful morphologic examination of bone marrow in CSF clinical trials will provide useful information regarding the in vivo effects of these growth factors, and will aid in the development of a rational approach to combining them for therapy.",
keywords = "Aplastic anemia, Bone marrow topography, GM-CSF, Hematopoiesis",
author = "F. Naeim and R. Champlin and Nimer, {Stephen D}",
year = "1990",
month = "1",
day = "1",
language = "English",
volume = "4",
pages = "79--85",
journal = "Hematologic Pathology",
issn = "0886-0238",
publisher = "Marcel Dekker Inc.",
number = "2",

}

TY - JOUR

T1 - Bone marrow changes in patients with refractory aplastic anemia treated by recombinant GM-CSF

AU - Naeim, F.

AU - Champlin, R.

AU - Nimer, Stephen D

PY - 1990/1/1

Y1 - 1990/1/1

N2 - The morphologic changes in the bone marrow of eight patients with refractory aplastic anemia who received 4 or more weeks of granulocyte macrophage-colony-stimulating factor (GM-CSF) are described. All eight patients demonstrated a continuous rise in the absolute number of neutrophils, eosinophils, and monocytes over the first four weeks of therapy. Bone marrow examination revealed a progressive increase in bone marrow cellularity in all patients except one. An increase in myeloid: erythroid ratio was seen with progressive maturation of granulocytic cells. Neutrophilic and eosinophilic myelocytes were the most prominent cells. The percentage of myeloblasts and promyelocytes did not increase significantly, and the proportions of postmitotic granulocytic cells did not change either. No significant morphologic changes were noted in the basophilic, erythroid, and megakaryocytic series. The most prominent topographic observation in the bone marrow during GM-CSF therapy was the frequent clustering of myeloid cells close to the bone trabeculae. The periosteal localization of myeloid precursors may reflect a higher concentration of stem cells and/or stromal cells in the bone marrow adjacent to the bone trabeculae or a higher concentration of growth factors. Careful morphologic examination of bone marrow in CSF clinical trials will provide useful information regarding the in vivo effects of these growth factors, and will aid in the development of a rational approach to combining them for therapy.

AB - The morphologic changes in the bone marrow of eight patients with refractory aplastic anemia who received 4 or more weeks of granulocyte macrophage-colony-stimulating factor (GM-CSF) are described. All eight patients demonstrated a continuous rise in the absolute number of neutrophils, eosinophils, and monocytes over the first four weeks of therapy. Bone marrow examination revealed a progressive increase in bone marrow cellularity in all patients except one. An increase in myeloid: erythroid ratio was seen with progressive maturation of granulocytic cells. Neutrophilic and eosinophilic myelocytes were the most prominent cells. The percentage of myeloblasts and promyelocytes did not increase significantly, and the proportions of postmitotic granulocytic cells did not change either. No significant morphologic changes were noted in the basophilic, erythroid, and megakaryocytic series. The most prominent topographic observation in the bone marrow during GM-CSF therapy was the frequent clustering of myeloid cells close to the bone trabeculae. The periosteal localization of myeloid precursors may reflect a higher concentration of stem cells and/or stromal cells in the bone marrow adjacent to the bone trabeculae or a higher concentration of growth factors. Careful morphologic examination of bone marrow in CSF clinical trials will provide useful information regarding the in vivo effects of these growth factors, and will aid in the development of a rational approach to combining them for therapy.

KW - Aplastic anemia

KW - Bone marrow topography

KW - GM-CSF

KW - Hematopoiesis

UR - http://www.scopus.com/inward/record.url?scp=0025372013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025372013&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 79

EP - 85

JO - Hematologic Pathology

JF - Hematologic Pathology

SN - 0886-0238

IS - 2

ER -